Atıf İçin Kopyala
Eralp Y., Keskin S., Akisik E. E., Akisik E., Igci A., Muslumanoglu M., ...Daha Fazla
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, cilt.36, sa.3, ss.215-223, 2013 (SCI-Expanded)
-
Yayın Türü:
Makale / Tam Makale
-
Cilt numarası:
36
Sayı:
3
-
Basım Tarihi:
2013
-
Doi Numarası:
10.1097/coc.0b013e318243913f
-
Dergi Adı:
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
-
Derginin Tarandığı İndeksler:
Science Citation Index Expanded (SCI-EXPANDED), Scopus
-
Sayfa Sayıları:
ss.215-223
-
Anahtar Kelimeler:
breast cancer, mRNA, response to neoadjuvant chemotherapy, survivin, GSTP1, topoisomerase 2A, GLUTATHIONE-S-TRANSFERASE, SURGICAL ADJUVANT BREAST, ANTHRACYCLINE-BASED CHEMOTHERAPY, PROJECT PROTOCOL B-27, II-ALPHA, PREOPERATIVE CHEMOTHERAPY, ESOPHAGEAL CANCER, SYSTEMIC THERAPY, TAXOL RESISTANCE, DRUG-RESISTANCE
-
İstanbul Üniversitesi Adresli:
Evet
Özet
Introduction: The primary aim of this study is to investigate the effect of change in the expression levels of survivin, glutathione-S-transferase P1 (GSTP1), and topoisomerase 2 alpha (TOP2A) on the response to antracyclin-based and taxane-based neoadjuvant chemotherapy.